Savara Inc (NASDAQ:SVRA) Director Joseph S. Mccracken Buys 10,000 Shares

Savara Inc (NASDAQ:SVRA - Get Free Report) Director Joseph S. Mccracken bought 10,000 shares of Savara stock in a transaction dated Thursday, May 29th. The shares were purchased at an average cost of $2.08 per share, for a total transaction of $20,800.00. Following the completion of the transaction, the director now owns 260,837 shares of the company's stock, valued at approximately $542,540.96. This represents a 3.99% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Savara Stock Down 4.2%

Shares of NASDAQ:SVRA traded down $0.11 during midday trading on Thursday, reaching $2.39. The company had a trading volume of 688,276 shares, compared to its average volume of 1,421,926. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The stock's fifty day moving average price is $2.89 and its 200-day moving average price is $2.93. The stock has a market capitalization of $412.22 million, a P/E ratio of -5.55 and a beta of 0.44. Savara Inc has a one year low of $1.89 and a one year high of $5.11.

Savara (NASDAQ:SVRA - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share for the quarter, meeting the consensus estimate of ($0.12). Equities research analysts expect that Savara Inc will post -0.45 earnings per share for the current fiscal year.

Institutional Trading of Savara

Several institutional investors have recently added to or reduced their stakes in SVRA. SG Americas Securities LLC increased its stake in Savara by 14.0% during the fourth quarter. SG Americas Securities LLC now owns 51,589 shares of the company's stock valued at $158,000 after purchasing an additional 6,330 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Savara by 14.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company's stock valued at $112,000 after purchasing an additional 4,732 shares during the last quarter. Rhumbline Advisers increased its stake in Savara by 6.8% during the fourth quarter. Rhumbline Advisers now owns 141,425 shares of the company's stock valued at $434,000 after purchasing an additional 9,041 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Savara by 7.6% during the fourth quarter. Bank of New York Mellon Corp now owns 253,630 shares of the company's stock valued at $779,000 after purchasing an additional 17,870 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in Savara by 5.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 963,821 shares of the company's stock valued at $2,959,000 after purchasing an additional 52,204 shares during the last quarter. Institutional investors own 87.93% of the company's stock.

Analyst Ratings Changes

SVRA has been the topic of a number of recent research reports. Guggenheim reissued a "buy" rating and set a $8.00 target price (down from $9.00) on shares of Savara in a research report on Wednesday, May 28th. Evercore ISI dropped their price target on shares of Savara from $3.00 to $2.00 and set an "in-line" rating for the company in a research note on Wednesday, May 28th. HC Wainwright lowered shares of Savara from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $6.00 to $2.00 in a research note on Thursday, May 29th. Finally, Wells Fargo & Company dropped their price target on shares of Savara from $8.00 to $7.00 and set an "overweight" rating for the company in a research note on Wednesday, May 28th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, Savara has an average rating of "Moderate Buy" and a consensus price target of $7.17.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.